Biotech firm shrugs off patent battle to market screening test in East Asia
Manchester biotech company Premaitha Health has shrugged off the disappointment of an adverse judgement in its multi-million pound patent battle in the UK with US company Illumina over its non-invasive prenatal test (NIPT) to forge a new agreement in East Asia.
In today’s announcement the company has stopped referring to the test, which detects Down’s syndrome and other genetic disorders in unborn children, as IONA.
The new partner is a private reference laboratory, which will provide the screening solution to its network of... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...
